Grantham, Mayo, Van Otterloo & Co (GMO)
IONS icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Ionis Pharmaceuticals IONS Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,700
Closed -$366K – 736
2022
Q4 		$366K Buy
+9,700
New +$408K ﹤0.01% 615

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s IONS Position: Q1 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Ionis Pharmaceuticals (IONS) in Q1 2023, closing a stake of 9,700 shares — an estimated $366K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in IONS in Q4 2022 and held it in 1 quarter. The position peaked at $366K in Q4 2022. 313 funds tracked by Wall St. Rank hold IONS as of Q1 2023.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Ionis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 9,700 Ionis Pharmaceuticals shares in Q1 2023, an estimated $366K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Ionis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Ionis Pharmaceuticals position peaked at $366K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2023, filed 12 May 2023.